Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties.
Last reviewed: 2026-08-18
Also known as
Status: Research compound / nootropic - not FDA approved
Full composition (formula, molecular weight, sequence) in Quick Facts →
Small clinical studies, mostly Russian, have reported cognitive improvements — e.g., in patients recovering from stroke when omberacetam was combined with physical rehabilitation. The evidence base is thin by Western standards: small samples, few independent replications, and no large multinational trials.
Rodent studies report improved learning and memory in amnesia models and neuroprotective effects, attributed in part to the active metabolite cycloprolylglycine (CPG) and glutamatergic (AMPA/NMDA) modulation.
Cell-based work characterizes omberacetam as a prodrug converted to cycloprolylglycine, with effects on glutamatergic signaling and neurotrophin-related pathways.
Claims that omberacetam is far more potent than piracetam, and of broad 'nootropic' benefits in healthy people, rest mainly on small Russian studies and animal data, with limited peer-reviewed replication.
In a clinical study, stroke patients receiving omberacetam (Noopept) alongside physical rehabilitation showed greater improvement in cognitive function and asthenic symptoms than rehabilitation alone.
No side effects data available yet.
This peptide may have limited safety data.
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
10mg
Research protocols are for educational purposes only. Always consult qualified medical professionals.
No. Omberacetam is not FDA approved; it is sold as a research/nootropic compound.
It is a prodrug converted to cycloprolylglycine (CPG), which is proposed to modulate glutamatergic (AMPA/NMDA) signaling and neuroplasticity-related pathways.
No — evidence is mostly from small Russian clinical studies and animal models; rigorous large trials in healthy adults are lacking.
Neuroprotection in Alzheimer's Model (2015)
(2015)
Neurotrophic Factor Expression (2009)
(2009)
Human Cognitive Enhancement Trial (2008)
(2008)
Mechanism
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Start with 10mg once daily to assess individual response before increasing dose. Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches. Avoid evening dosing as cognitive stimulation may interfere with sleep. Do not combine with other strong cholinergic or glutamatergic compounds without caution. Not recommended for pregnant or breastfeeding women due to lack of safety data. Individuals with liver conditions should consult healthcare provider before use.
1.Neuroprotection in Alzheimer's Model (2015)
(2015)
2.Neurotrophic Factor Expression (2009)
(2009)
3.Human Cognitive Enhancement Trial (2008)
(2008)